Arrowhead Pharmaceuticals, Inc. (LON:0HI3)
67.80
-1.66 (-2.39%)
Feb 6, 2026, 4:31 PM GMT
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $264.03M USD in the quarter ending December 31, 2025, with 10,461.32% growth. This brings the company's revenue in the last twelve months to $1.09B. In the fiscal year ending September 30, 2025, Arrowhead Pharmaceuticals had annual revenue of $829.45M with 23,258.15% growth.
Revenue (ttm)
$1.09B
Revenue Growth
+23,258.15%
P/S Ratio
8.25
Revenue / Employee
$1.53M
Employees
711
Market Cap
6.69B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | 168.80M | 152.65M | 945.67% |
| Sep 30, 2018 | 16.14M | -15.27M | -48.60% |
| Sep 30, 2017 | 31.41M | 31.25M | 19,736.49% |
| Sep 30, 2016 | 158.33K | -223.67K | -58.55% |
| Sep 30, 2015 | 382.00K | 207.00K | 118.29% |
| Sep 30, 2014 | 175.00K | -115.27K | -39.71% |
| Sep 30, 2013 | 290.27K | 143.39K | 97.63% |
| Sep 30, 2012 | 146.88K | -149.26K | -50.40% |
| Sep 30, 2011 | 296.14K | - | - |
| Sep 30, 2010 | - | - | - |
| Sep 30, 2009 | 3.76M | 2.45M | 188.38% |
| Sep 30, 2008 | 1.30M | 95.18K | 7.88% |
| Sep 30, 2007 | 1.21M | 746.74K | 161.88% |
| Sep 30, 2006 | 461.28K | -129.40K | -21.91% |
| Sep 30, 2005 | 590.68K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.80M |
| Oxford Nanopore Technologies | 204.69M |
| Oxford Biomedica | 151.21M |
| Bioventix | 13.12M |
| Scancell Holdings | 4.71M |
| PureTech Health | 4.66M |
| SkinBioTherapeutics | 4.64M |
| 4basebio | 1.78M |
Arrowhead Pharmaceuticals News
- 10 days ago - Arrowhead (ARWR) Advances with New Atherosclerosis Treatment Trial - GuruFocus
- 10 days ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Business Wire
- 15 days ago - Arrowhead Pharma (ARWR): B. Riley Securities Raises Price Target Significantly | ARWR Stock News - GuruFocus
- 16 days ago - Arrowhead Pharma (ARWR) Sees Target Price Boost by HC Wainwright & Co. | ARWR Stock News - GuruFocus
- 16 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results - Business Wire
- 22 days ago - ARWR September 18th Options Begin Trading - Nasdaq
- 24 days ago - Arrowhead Pharma (ARWR) Price Target Raised by Piper Sandler | ARWR Stock News - GuruFocus
- 24 days ago - Arrowhead Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus